Výsledky vyhledávání - "Klein, S. K."

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Publikováno v: Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287a701a807a9162ad042541d5d386bd
http://www.scopus.com/inward/record.url?scp=85134692962&partnerID=8YFLogxK

Zobrazit plný text záznamu

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Autor: Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J.

Publikováno v: Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4231d8d48f8da424335ae95804aeb6bc
https://research.vumc.nl/en/publications/05f113e6-d597-4250-99cf-855010361d8a

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

Autor: Zweegman, S., Levin, M. -D., Klein, S. K., de Waal, E. G., Eeltink, C. M., Ypma, P. F., Dijk, A. C., Westerman, M., Deenik, W., Tanis, B., Slee-Valentijn, M. S., Minnema, M. C., Visser-Wisselaar, H., Stege, C., van de Donk, N. W., Nasserinejad, K., Sonneveld, P.

Publikováno v: Haematologica, 102, 112-113. Ferrata Storti Foundation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::d4d40a77be21da69f022ffdde82a96f0
https://research.vumc.nl/en/publications/990c826d-87ef-4f9d-9658-607361930cdf

Zobrazit plný text záznamu

Richtlijn behandeling multipel myeloom 2015

Autor: Zweegman, S., Lokhorst, H. M., Levin, M. D., de Waal, E., Bos, G. M. J., Kersten, M. J., Croockewit, A., Ypma, P. F., Klein, S. K., Minnema, M. C., Sonneveld, P.

Publikováno v: Nederlands Tijdschrift voor Hematologie, 12(8), 279-302
Zweegman, S, Lokhorst, H M, Levin, M D, de Waal, E, Bos, G M J, Kersten, M J, Croockewit, A, Ypma, P F, Klein, S K, Minnema, M C & Sonneveld, P 2015, ' Richtlijn behandeling multipel myeloom 2015 ', Nederlands Tijdschrift voor Hematologie, vol. 12, no. 8, pp. 279-302 . < http://www.ariez.nl/artikelen.1206.lynkx?edition=9d96fccd-4126-405d-92a0-37d823d87362&author=&title=&keyword=&free=&event=search&tijdschrift=ntvh >
Nederlands tijdschrift voor hematologie, 12(8), 279-302

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3ee7fd001bfbdb10dca126a1b54ee872
https://research.vumc.nl/en/publications/15c1e57a-8291-42f6-8174-9d8a11428c26

Zobrazit plný text záznamu

Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia

Autor: Vos, J. M. I., Minnema, M. C., Wijermans, P. W., Croockewit, S., Chamuleau, M. E. D., Steven Pals, Klein, S. K., Delforge, M., Imhoff, G. W., Kersten, M. J.

Publikováno v: Netherlands Journal of Medicine, 71, 2, pp. 54-62
Scopus-Elsevier
Vos, J M I, Minnema, M C, Wijermans, P W, Croockewit, S, Chamuleau, M E D, Pals, S T, Klein, S K, Delforge, M, van Imhoff, G W & Kersten, M J 2013, ' Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia ', Netherlands Journal of Medicine, vol. 71, no. 2, pp. 54-62 .
Netherlands Journal of Medicine, 71(2), 54-62. Van Zuiden Communications BV
Netherlands Journal of Medicine, 71, 54-62

Item does not contain fulltext On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of Waldenstrom's

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6d253ef35d3ce7ee58b53b7e8935576f
https://hdl.handle.net/2066/118505

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání